Wrong concentration, double dose
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Without access to the underlying clinical data from the VA program referenced in the title, including sample size, primary and secondary endpoints, baseline characteristics, and reported outcomes with confidence intervals or p-values, a clinically accurate summary cannot be produced
This verifies that the compound matches what's claimed on the label, essential for ensuring research validity
While it may contribute to modest improvements in fat loss and exercise performance, it works best when combined with a healthy diet and regular exercise